Reports

Drug name	NICE TAs	Comments
Bimekizumab	TA723 - Bimekizumab for treating moderate to severe plaque psoriasis TA916 - Bimekizumab for treating active psoriatic arthritis
Birch bark extract (Filsuvez ®gel)	HST28: Birch bark extract for treating epidermolysis bullosa
Blinatumomab	TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	Hospital use only
Bortezomib injection	TA228 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA129 - Bortezomib monotherapy for relapsed multiple myeloma TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	National CDF list. Hospital use only.
Bosutinib	TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Botox A	TA260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab injection	TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	National CDF list. For hospital use only.
Brentuximab vedotin (Adcetris®)	NICE TA 1059 Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma
Brexucabtagene autoleucel	TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Brigatinib (Alunbrig®)	TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib TA670 - Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports